

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
A0000434-01-CFP

In Re Application: **CHARLES ANDRIANJARA, ET AL**

Serial No.

10/075,069

Filing Date

February 13, 2002

Examiner


Unknown

Group Art Unit

1614

MATRIX METALLOPROTEINASE INHIBITORS

MAY 29 2002



RECEIVED

JUN 04 2002

TECH CENTER 1600/2900

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 23-0455 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited May 23, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Nancy Dernbach

Signature of Person Mailing Correspondence

Nancy Dernbach

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Claude F. Purchase, Jr.

Signature

Dated: May 23, 2002

Claude F. Purchase, Jr.
Registration No. 47,871
Warner-Lambert Company
Patent Department
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1692
Fax (734) 622-1553

cc:

GP/1614 #7
8/8/0
82

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
A0000434-01-CFP

In Re Application Of: **CHARLES ANDRIANJARA, ET AL**

Serial No.
10/075,069

Filing Date
February 13, 2002

Examiner
Unknown

Group Art Unit
1614

Title: **MATRIX METALLOPROTEINASE INHIBITORS**



RECEIVED
JUN 04 2002
TECH CENTER 1600/2900

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).